Inclusion Criteria:

          1. Relapsed and refractory B-cell acute malignancies with:

               -  Relapsed after competed remission, could not get competed remission after at more
                  than 1 course of chemotherapy (including MRD≥0.1%);

               -  MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or
                  recurrence after complete remission or MRD ≥ 0.1% after HSCT;

               -  Refractory: at least two courses of chemotherapy did not achieve complete
                  remission or MRD ≥ 0.1%;

          2. Patients must have evaluable evidence of disease, including minimal residual disease
             (MRD);

          3. Ph + patients who meet the following criteria can register:Failure to tolerate TKI or
             TKI treatment failure, or failure to transplant;

          4. Double positive expression of CD19 / CD20 in B cells;

          5. Ages 1 to 70 years, including boundary values;

          6. ECOG score 0-3 points;

          7. Women of childbearing age (15-49 years old) must receive a pregnancy test within 7
             days prior to initiation of treatment and the results are negative; male and female
             patients with fertility must use an effective contraceptive to ensure 3 months after
             discontinuation of treatment during the study period not pregnant inside.

          8. Patients who voluntarily sign informed consent and are willing to comply with
             treatment plans.

        Exclusion Criteria:

          1. patients with organ failure:

               -  Heart: NYHA heart function grade IV;

               -  Liver: Grade C that achieves Child-Turcotte liver function grading;

               -  Kidney: kidney failure and uremia;

               -  Lung: symptoms of respiratory failure;

               -  Brain: a person with a disability;

          2. Active infections that are difficult to control;

          3. Human immunodeficiency virus (HIV) positive;

          4. Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST)
             and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL /
             min;

          5. GVHD ≥ 2 or anti-GVHD treatment;

          6. Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion;

          7. Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1
             week;

          8. Central nervous system white blood that is symptomatic or uncontrolled by systemic
             chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white
             blood cell count >15WBCs/mL);

          9. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular
             internal coagulation;

         10. pregnant or lactating women;

         11. The patient does not agree to use effective contraception during the treatment period
             and for the next 3 months;

         12. Patients who participate in other clinical studies at the same time;

         13. The investigator believes that there are other factors that are not suitable for
             inclusion or influence the subject's participation or completion of the study.